Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model

Abstract

For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapy after surgical transurethral resection. Bacillus Calmette-Guerin (BCG) is a live attenuated Mycobacterium of the same family as tuberculosis, that is capable of inducing a local inflammatory response upon instillation into the bladder. Intravesical therapy with BCG has proved to be more effective in the prophylaxis and treatment of superficial bladder tumors than most chemotherapeutic agents used for the same indication. However, compared to intravesical chemotherapy, BCG immunotherapy provokes more pronounced local and systemic reactions. In addition to the commonly induced granulomatous inflammatory changes in the bladder, which produce irritative symptoms, this therapy may cause systemic side effects varying from mild malaise and fever to, in rare instances, life-threatening or fatal sepsis. Nanoparticles with positive surface charge and mucoadhesive properties were developed to overcome these side effects. Hence, the aim of this study was to optimize and evaluate cationic chitosan (CS) nanoparticles encapsulating BCG in terms of antitumor efficacy after intravesical administration in bladder tumor, induced in rat model. It was found that nanoparticle formulations of 269-375 nm in size can be produced with 42% encapsulation efficiency. The zeta potential was positive and was suitable for intravesical administration. Antitumor efficacy was determined over the parameters of histopathological evaluation, survival rate and mean bladder weight in comparison to treatment with commercial BCG solution. Concerning survival rates, BCG-loaded chitosan nanoparticles resulted in significantly longer survival than BCG commercial product (up to 86 days of survival with no systemic side effects). When compared to healthy bladder weight averages, all groups (especially BCG commercial solution) showed higher bladder weights confirming tumor formation. Histopathological findings confirmed antitumor activity in all treatment groups and optimum findings were observed in groups treated with CS nanoparticles encapsulating BCG. At the same time, significant nanoparticle accumulation in bladder tissues was observed especially for BCG-loaded CS group. In this study, it was clearly observed that cationic CS nanoparticles provide a significantly improved perspective in intravesical immunotherapy of bladder tumors.

Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

“…In this sense, a critical point for mycobacteria efficacy is the delivery of mycobacteria or mycobacteria antigens into the tumor site. The optimization of mycobacteria formulation could be critical for reducing adverseassociated events [97] and/or improving mycobacteria antitumor efficacy [77]. Moreover, the possibility to manipulate genetically mycobacteria for being vehicle for delivery antigens could lead also a chance to get more potent antitumor tools.…”

Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation

“…Transurethral resection of the tumor is the first-choice treatment for such patients, but it commonly results in tumor relapse, and thus more aggressive therapies are needed. 6 – 8 Although a number of treatment strategies, including systemic immunotherapy/chemotherapy and radiotherapy, have been used recently, the overall survival rate has not improved, and bladder cancer is associated with serious morbidity and even mortality. Therefore, it is clear that alternative treatment approaches for bladder cancer are still needed.…”

Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles

“…Indeed, since dissociation takes place too readily upon dilution, untimely release may take place during administration to the patient, so that inclusion complexes inside simple water-soluble CD appear ineffective for drug delivery applications. In fact, the use of amphiphilic CDs (i) enhances the interaction with biological membranes, (ii) modifies or enhances interaction of CDs with hydrophobic drugs, and (iii) allows self-assembly of CDs, forming nanosized carriers and encapsulating drugs 25 , 26 . Polycationic CD nanoparticles containing siRNA have been recently used for the delivery of siRNA to the glomerular mesangium 27 .…”